Cerenis Therapeutics announced the appointment of Barbara Yanni to its Board of Directors as an Independent director. Barbara is currently an Independent Director of three other clinical-stage biotech companies: Trevena Inc., Vaccinex Inc. and Symic Bio. She has more than thirty years of experience in pharma and biotechnology. As Chief Licensing Officer at Merck & Co. Inc. she has built strong relationships within the pharmaceutical, biotech and venture community. She oversaw successful strategic collaborations for 33 clinical and/or commercial compounds, 13 preclinical compounds and more than 100 compounds at the discovery, formulation or research technology stage. Prior to her leadership roles in business development at Merck, Barbara conducted financial analyses of business development opportunities and employee benefits and devised and implemented strategies to minimize Merck’s corporate taxes.